2-(Piperidin-4-yl)ethanol(cas: 622-26-4) can be used to synthese ursolic acid derivatives, spiroimidazolidinone NPC1L1 inhibitors, neurokinin-2 receptor antagonists, antagonists for inhibition of platelet aggregation.Electric Literature of C7H15NO
In 2019,Proceedings of the National Academy of Sciences of the United States of America included an article by Hong, W. David; Benayoud, Farid; Nixon, Gemma L.; Ford, Louise; Johnston, Kelly L.; Clare, Rachel H.; Cassidy, Andrew; Cook, Darren A. N.; Siu, Amy; Shiotani, Motohiro; Webborn, Peter J. H.; Kavanagh, Stefan; Aljayyoussi, Ghaith; Murphy, Emma; Steven, Andrew; Archer, John; Struever, Dominique; Frohberger, Stefan J.; Ehrens, Alexandra; Hubner, Marc P.; Hoerauf, Achim; Roberts, Adam P.; Hubbard, Alasdair T. M.; Tate, Edward W.; Serwa, Remigiusz A.; Leung, Suet C.; Qie, Li; Berry, Neil G.; Gusovsky, Fabian; Hemingway, Janet; Turner, Joseph D.; Taylor, Mark J.; Ward, Stephen A.; O’Neill, Paul M.. Electric Literature of C7H15NO. The article was titled 《AWZ1066S, a highly specific anti-Wolbachia drug candidate for a short-course treatment of filariasis》. The information in the text is summarized as follows:
Onchocerciasis and lymphatic filariasis are two neglected tropical diseases that together affect ∼ 157 million people and inflict severe disability. Both diseases are caused by parasitic filarial nematodes with elimination efforts constrained by the lack of a safe drug that can kill the adult filaria (macrofilaricide). Previous proof-of-concept human trials have demonstrated that depleting > 90% of the essential nematode endosymbiont bacterium, Wolbachia, using antibiotics, can lead to permanent sterilization of adult female parasites and a safe macrofilaricidal outcome. AWZ1066S is a highly specific anti-Wolbachia candidate selected through a lead optimization program focused on balancing efficacy, safety and drug metabolism/pharmacokinetic (DMPK) features of a thienopyrimidine/quinazoline scaffold derived from phenotypic screening. AWZ1066S shows superior efficacy to existing anti-Wolbachia therapies in validated preclin. models of infection and has DMPK characteristics that are compatible with a short therapeutic regimen of 7 days or less. This candidate mol. is well-positioned for onward development and has the potential to make a significant impact on communities affected by filariasis. The experimental process involved the reaction of 2-(Piperidin-4-yl)ethanol(cas: 622-26-4Electric Literature of C7H15NO)
2-(Piperidin-4-yl)ethanol(cas: 622-26-4) can be used to synthese ursolic acid derivatives, spiroimidazolidinone NPC1L1 inhibitors, neurokinin-2 receptor antagonists, antagonists for inhibition of platelet aggregation.Electric Literature of C7H15NO
Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem